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Objective: Ischemic preconditioning combined with potassium cardioplegia
does not always confer additive myocardial protection. This study tested the
hypothesis that the efficacy of ischemic preconditioning under potassium
cardioplegia is dependent on protein kinase C isoform.
Methods: Isolated and crystalloid-perfused rat hearts underwent 5 cycles of
1 minute of ischemia and 5 minutes of reperfusion (low-grade ischemic pre-
conditioning) or 3 cycles of 5 minutes of ischemia and 5 minutes of reperfu-
sion (high-grade ischemic preconditioning) or time-matched continuous per-
fusion. These hearts received a further 5 minutes of infusion of normal buffer
or oxygenated potassium cardioplegic solution. The isoform nonselective
protein kinase C inhibitor chelerythrine (5 µmol/L) was administered
throughout the preischemic period. All hearts underwent 35 minutes of nor-
mothermic global ischemia followed by 30 minutes of reperfusion.
Isovolumic left ventricular function and creatine kinase release were mea-
sured as the end points of myocardial protection. Distribution of protein
kinase C α, δ, and ε in the cytosol and the membrane fractions were analyzed
by Western blotting and quantified by a densitometric assay.
Results: Low-grade ischemic preconditioning was almost as beneficial as
potassium cardioplegia in improving functional recovery; left ventricular
developed pressure 30 minutes after reperfusion was 70 ± 15 mm Hg 
(P < .01) in low-grade ischemic preconditioning and 77 ± 14 mm Hg 
(P < .001) in potassium cardioplegia compared with values found in unpro-
tected control hearts (39 ± 12 mm Hg). Creatine kinase release during reper-
fusion was also equally inhibited by low-grade ischemic preconditioning
(18.2 ± 10.6 IU/g dry weight, P < .05) and potassium cardioplegia (17.6 ±
6.7 IU/g, P < .01) compared with control values. However, low-grade
ischemic preconditioning in combination with potassium cardioplegia con-
ferred no significant additional myocardial protection; left ventricular devel-
oped pressure was 80 ± 17 mm Hg, and creatine kinase release was 14.8 ±
11.0 IU/g. In contrast, high-grade ischemic preconditioning with potassium
cardioplegia conferred better myocardial protection than potassium cardio-
plegia alone; left ventricular developed pressure was 121 ± 16 mm Hg (P <
.001), and creatine kinase release was 8.3 ± 5.8 IU/g (P < .05). Chelerythrine
itself had no significant effect on functional recovery and creatine kinase
release in the control hearts, but it did inhibit the salutary effects not only of
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I schemic preconditioning (IPC) is known as a power-ful form of endogenous myocardial protection
against necrosis, contractile dysfunction, and arrhyth-
mias during ischemia and reperfusion.1-3 Although
numerous studies have proven the benefit of IPC in
myocardial protection in regional or global models of
unprotected ischemia, the efficacy of IPC when com-
bined with potassium cardioplegia (PCP) remains con-
troversial.4-9 Previous studies, including our own,7,8
have demonstrated that IPC and PCP confer an equally
beneficial effect on postischemic functional recovery,
whereas combination of the 2 techniques afforded no
significant additional protection. These studies have
suggested that IPC and PCP share a common mecha-
nism for myocardial protection. However, a certain pre-
conditioning challenge could enhance myocardial pro-
tection under PCP in the clinical setting.10 It is
therefore important to elucidate the additional mecha-
nism underlying synergistic myocardial protection by
IPC to invent the strategy for myocardial protection
during cardiac operations.
IPC is known to be a graded phenomenon in which
intracellular signaling pathways and its potency of
myocardial protection depend on the duration and num-
ber of cycles of ischemia and reperfusion.11-13 It is pos-
sible that suboptimal IPC protocols against unprotected
ischemia do not enhance myocardial protection when
combined with PCP because of a common mechanism
of protection, whereas optimal IPC protocols against
unprotected ischemia may also confer additive myocar-
dial protection under PCP. Although the mechanisms
by which IPC produces myocardial protection remain
elusive, a growing body of evidence suggests that pro-
tein kinase C (PKC) is involved in myocardial protec-
tion induced by IPC. Moreover, it is increasingly clear
that different preconditioning stimuli provoke the acti-
vation of distinct PKC isoforms, which play a distinct
role in myocardial protection.14,15 PKC isoforms in the
adult rat heart are subdivided into 3 groups according
to the requirement of different cofactors for activa-
tion.16 PKC α, β1, β2, and γ isoforms require both Ca2+
and lipids (ie, phosphatidylserine and diacylglycerol)
for their activation. The subfamily of novel PKC iso-
forms, which includes PKC ζ, ε, η, θ, and µ, do not
require Ca2+, but as with the classical isoforms, still
require lipids for activation. The subfamily of atypical
PKC isoforms includes PKC ζ, ι, and λ, which require
phosphatidylserine for its activity, but neither Ca2+ nor
diacylglycerol are needed for their activation. In the
adult rat heart PKC α, δ, and ε have been considered to
be critical mediators for myocardial protection by
IPC.17-19 These isoforms are translocated to the mem-
brane and activated at different stages of myocardial
ischemia and on administration of Ca2+ loading or
chemical agonists, such as adenosine and phorbol
esters.15,16,20,21 Thus, it is anticipated that the efficacy
of IPC when combined with PCP is determined by the
grade of IPC and is dependent on which PKC isoforms
are activated during IPC challenges. Therefore, the
present study was undertaken to test this hypothesis by
using low-grade or high-grade IPC, which confers sub-
optimal or optimal myocardial protection, respectively,
against unprotected ischemia.
Materials and methods
Perfusion technique.  Male Sprague-Dawley rats weigh-
ing 250 to 300 g were used in the present study. These ani-
mals received humane care according to the animal welfare
regulations of the Kansai Medical University and were quar-
antined in quiet quarters for at least a week before the study.
The rats were anesthetized intraperitoneally with pentobarbi-
tal sodium (100 mg/kg). After thoracotomy, the hearts were
rapidly excised and placed in a Langendorff apparatus. The
hearts were perfused at a constant mean pressure of 70 to 75
mm Hg with Krebs-Henseleit bicarbonate buffer solution
(composition: 118 mmol/L NaCl, 4.7 mmol/L KCl, 1.2
mmol/L MgSO4, 25 mmol/L NaHCO3, 1.2 mmol/L KH2PO4,
138 Lu et al The Journal of Thoracic and
Cardiovascular Surgery
January 2001
sium cardioplegia. Low-grade ischemic preconditioning and potassium car-
dioplegia enhanced translocation of protein kinase C α to the membrane,
whereas high-grade ischemic preconditioning also enhanced translocation
of protein kinase C δ and ε. Chelerythrine inhibited translocation of all 3
protein kinase C isoforms.
Conclusions: These results suggest that myocardial protection by low-grade
ischemic preconditioning and potassium cardioplegia are mediated through
enhanced translocation of protein kinase C α to the membrane. It is there-
fore suggested that activation of the novel protein kinase C isoforms is nec-
essary to potentiate myocardial protection under potassium cardioplegia.  
(J Thorac Cardiovasc Surg 2001;121:137-48)
2.5 mmol/L CaCl2, and 11 mmol/L glucose; pH 7.4) at 37°C
when equilibrated with a mixture of 95% oxygen and 5% car-
bon dioxide gas.
During the stabilization period, a latex balloon was insert-
ed into the left ventricle through the left atrium to measure
isovolumic left ventricular function. The balloon was filled
with saline solution to produce a left ventricular end-diastolic
pressure (LVEDP) of 5 to 10 mm Hg at baseline, and the bal-
loon volume was kept constant throughout the experiment.
Coronary flow (CF) was measured by timed collection of the
coronary effluent. Hearts producing a left ventricular devel-
oped pressure (LVDP) of lower than 100 mm Hg or a heart
rate (HR) of less than 240 beats/min at baseline were exclud-
ed from the study.
Experimental protocol. The hearts were randomly
assigned to 12 groups (Fig 1). Time-matched control hearts
underwent 45 minutes of normal perfusion before 35 minutes
of normothermic global ischemia (unprotected ischemia) fol-
lowed by 30 minutes of reperfusion. Low-grade or high-
grade IPC was induced by 5 cycles of 1 minute of ischemia
and 5 minutes of reperfusion or 3 cycles of 5 minutes of
ischemia and 5 minutes of reperfusion, respectively. In these
groups of hearts the last reperfusion of IPC before the sus-
tained period of ischemia was extended to 10 minutes to
match the time frame with the hearts in the PCP groups. The
hearts in the PCP groups received 40 minutes of normal per-
fusion followed by 5 minutes of infusion of potassium-rich
Krebs-Henseleit bicarbonate buffer solution (containing 20
mmol/L KCl with equimolar reduction of NaCl) equilibrated
with a mixture of 95% oxygen and 5% carbon dioxide gas,
pH 7.4, before the sustained period of ischemia. Low-grade
or high-grade IPC was also introduced in these groups of
hearts before receiving PCP. The isoform nonselective PKC
inhibitor chelerythrine (Research Biochemical International
Inc, Natick, Mass) at a concentration of 5 µmol/L, which is
known to inhibit PKC activity specifically, was administered
for 45 minutes before 35 minutes of ischemia in all the chel-
erythrine-treated groups.
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Fig 1.  Experimental protocols. L-IPC, Low-grade IPC induced by 5 cycles of 1 minute of ischemia and 5 minutes
of reperfusion; H-IPC, high-grade IPC induced by 3 cycles of 5 minutes of ischemia and 5 minutes of reperfusion;
Che, 5 µmol/L chelerythrine. Filled boxes, Ischemia; hatched boxes, oxygenated PCP.
Coronary effluent was collected during 30 minutes of
reperfusion, and creatine kinase activity was measured by an
enzymatic assay method22 to assess the severity of myocar-
dial injury. At the end of the experiment, a piece of the left
ventricular tissue was excised to determine the wet/dry ratio.
In the experiments on PKC assay, left ventricular
myocardium of approximately 500 mg was excised at the end
of IPC, PCP, or time-matched normal perfusion. The myocar-
dial samples were immediately frozen in liquid nitrogen and
kept at –80°C until use. 
Tissue sample preparation. Frozen myocardial tissue
samples were powdered under liquid nitrogen and homoge-
nized in 5 volumes of buffer containing 320 mmol/L sucrose,
10 mmol/L Tris-HCl, 1 mmol/L ethyleneglycol-bis-(β-
aminoethylether)-N-N-N′-N′-tetraacetic acid, 1 mmol/L eth-
ylenediamine tetraacetic acid, 10 mmol/L benzamidine, 50
mmol/L NaF, 50 µg/mL phenylmethylsulfonyl fluoride, 10
µg/mL aprotinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin A,
and 0.3% β-mercaptoethanol with a Polytron homogenizer
(Brinkman Instruments, Inc, Westbury, NY) at the maximum
speed 3 times for 15 seconds each. The homogenates were
mixed with an equal volume of the same buffer and cen-
trifuged at 1000g for 10 minutes, and then the supernatant
was centrifuged at 100,000g for 60 minutes. The 100,000g
pellet was designated the membrane fraction, whereas the
100,000g supernatant was referred to as the cytosol fraction.
Protein concentrations were determined by the method of
Bradford23 by means of an assay kit (Bio-Rad Laboratories,
Yokohama, Japan).
Immunoblotting and quantification of PKC. The frac-
tions were subjected to sodium dodecylsulfate-polyacryl-
amide gel electrophoresis in 7.5% polyacrylamide gels and
then immunoblotted according to the method of Yoshida and
associates.24 The blots were blocked with 5% skim milk in
buffer containing 150 mmol/L NaCl, 10 mmol/L Tris-HCl
(pH 7.4), and 0.05% Tween-20 for at least 1 hour and then
incubated with one of the 2000- to 3000-fold diluted anti-
bodies against PKC isoforms for 1 hour at room temperature,
and the PKC isoforms were visualized by the use of an ECL
Western blotting detection kit. The amounts of PKC isoforms
on the immunoblots were measured with a densitometric
analysis by use of the NIH Image program (NIH-Image ver-
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Table I. Effect of IPC on cardiac performance
Reperfusion (min)
Baseline Before ischemia 10 20 30
LVDP (mm Hg)
Control (n = 7) 126 ± 13 126 ± 9 27 ± 10 36 ± 12 39 ± 12
L-IPC (n = 6) 125 ± 14 119 ± 15 54 ± 14* 63 ± 15† 70 ± 15†
H-IPC (n = 6) 119 ± 11 78 ± 8‡ 70 ± 19‡ 81 ± 18‡ 87 ± 12‡
Che (n = 6) 121 ± 9 130 ± 9 28 ± 16 41 ± 15 44 ± 16
Che + L-IPC (n = 6) 127 ± 15 130 ± 8 31 ± 18§ 42 ± 18 44 ± 19§
Che + H-IPC (n = 6) 128 ± 10 100 ± 19*§ 38 ± 21§ 48 ± 19§ 50 ± 17
HR (beats/min)
Control 298 ± 30 298 ± 28 188 ± 29 190 ± 25 193 ± 23
L-IPC 298 ± 14 296 ± 14 225 ± 34 232 ± 36* 233 ± 35*
H-IPC 303 ± 23 276 ± 16 217 ± 30 223 ± 24* 225 ± 27*
Che 296 ± 26 294 ± 19 194 ± 33 197 ± 32 197 ± 29
Che + L-IPC 300 ± 18 300 ± 18 188 ± 33 201 ± 24 204 ± 18
Che + H-IPC 305 ± 27 298 ± 20 205 ± 53 213 ± 48 218 ± 43
CF (mL · min–1 · g–1 dry weight)
Control 58 ± 6 59 ± 6 45 ± 6 48 ± 6 48 ± 5
L-IPC 59 ± 5 69 ± 6* 58 ± 8† 61 ± 7† 61 ± 8†
H-IPC 57 ± 7 79 ± 11† 65 ± 7‡ 67 ± 7‡ 67 ± 6‡
Che 61 ± 7 65 ± 5 46 ± 6 49 ± 6 49 ± 6
Che + L-IPC 63 ± 7 70 ± 9* 48 ± 5§ 50 ± 6§ 50 ± 6§
Che + H-IPC 58 ± 8 84 ± 10‡ 49 ± 6 52 ± 6 52 ± 6
LVEDP (mm Hg)
Control 7 ± 2 7 ± 2 65 ± 10 55 ± 11 51 ± 10
L-IPC 8 ± 2 8 ± 2 43 ± 11† 35 ± 6† 32 ± 6†
H-IPC 7 ± 1 7 ± 1 32 ± 7‡ 27 ± 6‡ 26 ± 6‡
Che 7 ± 2 7 ± 2 58 ± 11 52 ± 9 47 ± 10
Che + L-IPC 8 ± 2 7 ± 2 57 ± 9§ 48 ± 10§ 46 ± 10§
Che + H-IPC 8 ± 2 8 ± 2 53 ± 11 45 ± 11 42 ± 11§
Data are expressed as mean ± SD. L-IPC, Low-grade IPC; H-IPC, high-grade IPC; Che, chelerythrine.
*P < .05, †P < .01, and ‡P < .001 compared with control hearts.
§P < .05 and P < .01 compared with respective IPC without Che.
sion 1.59). Consistency in the data analysis was ensured by
running the cytosolic and membrane fractions of all 5 tissue
samples in each group on the same gel. Each immunoblotting
experiment was repeated twice, and the results were aver-
aged. The total amounts of protein transferred from each lane
to the nitrocellulose membranes during blotting were rarely
identical, despite a careful attempt to achieve equal protein
loading in all lanes of the gel, and therefore each PKC iso-
form signal was normalized to the corresponding Coomassie
Blue stain signal determined by densitometric analysis, as
described by Ping and coworkers.25 Rabbit polyclonal anti-
bodies against PKC isoforms α, δ, and ε were obtained from
Santa Cruz Biotechnology Inc (Santa Cruz, Calif). Relative
distribution of each PKC isoform in the membrane fraction
was calculated by dividing the normalized PKC isoform sig-
nal in the membrane fraction by the normalized PKC isoform
signal in the cytosol fraction. The values were presented as a
percentage of the cytosol fraction.
Statistical analysis.  All data are expressed as means ± SD.
Statistical analysis was performed by using 1-way analysis of
variance and the Scheffé multiple comparison test.
Results
Effect of IPC on cardiac performance. Table I shows the
effect of low- or high-grade IPC without PCP on cardiac
performance in the isolated rat heart. None of the base-
line hemodynamic variables significantly differed among
the 6 groups. LVDP was significantly depressed by high-
grade IPC but not by low-grade IPC. The recovery of
LVDP during reperfusion was significantly greater in the
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Table II. Effect of IPC and PCP on cardiac performance
Reperfusion (min)
Baseline Pre-PCP 10 20 30
LVDP (mm Hg)
Control (n = 7) 126 ± 13 126 ± 9 27 ± 9 36 ± 12 39 ± 12
PCP (n = 7) 123 ± 13 125 ± 11 61 ± 19† 72 ± 16‡ 77 ± 14‡
L-IPC + PCP (n = 6) 129 ± 15 126 ± 15 63 ± 19† 77 ± 16‡ 80 ± 17‡
H-IPC + PCP (n = 6) 120 ± 10 76 ± 15‡,¶ 108 ± 22‡, 123 ± 21‡,¶ 121 ± 16‡,¶
Che + PCP (n = 6) 124 ± 10 127 ± 7 31 ± 18§ 47 ± 19§ 52 ± 16§
Che + L-IPC + PCP (n = 6) 130 ± 12 128 ± 12 39 ± 15§,# 53 ± 12*,§,# 56 ± 10*,§,#
Che + H-IPC + PCP (n = 6) 126 ± 15 103 ± 14*,§,# 51 ± 12†,†† 70 ± 19†,†† 74 ± 10‡,††
HR (beats/min)
Control 298 ± 30 298 ± 28 188 ± 29 190 ± 25 193 ± 23
PCP 301 ± 14 298 ± 29 209 ± 57 232 ± 42* 234 ± 39*
L-IPC + PCP 295 ± 31 293 ± 21 203 ± 35 240 ± 36* 242 ± 35*
H-IPC + PCP 302 ± 29 299 ± 23 276 ± 36‡, 276 ± 50‡,§ 289 ± 60‡,§
Che + PCP 299 ± 18 297 ± 16 184 ± 37 189 ± 33# 189 ± 30#
Che + L-IPC + PCP 302 ± 20 300 ± 22 182 ± 40 196 ± 34# 196 ± 36#
Che + H-IPC + PCP 305 ± 27 298 ± 25 221 ± 16# 226 ± 15# 229 ± 14*,#
CF (mL · min–1 · g–1 dry weight)
Control 58 ± 6 59 ± 6 45 ± 6 48 ± 6 48 ± 5
PCP 60 ± 6 60 ± 5 58 ± 7† 59 ± 9* 58 ± 7†
L-IPC + PCP 61 ± 5 68 ± 6*,§ 61 ± 7† 62 ± 7† 61 ± 7†
H-IPC + PCP 62 ± 8 76 ± 10†, 62 ± 5‡ 63 ± 4‡ 64 ± 3‡
Che + PCP 60 ± 8 65 ± 8 49 ± 6 49 ± 6§,# 49 ± 6§,#
Che + L-IPC + PCP 60 ± 9 70 ± 10*,§ 51 ± 9 50 ± 8# 51 ± 9#
Che + H-IPC + PCP 61 ± 9 82 ± 11‡,¶ 54 ± 5*,# 55 ± 5# 55 ± 5**
LVEDP (mm Hg)
Control 7 ± 2 7 ± 2 65 ± 10 55 ± 11 50 ± 10
PCP 6 ± 2 6 ± 2 36 ± 11‡ 35 ± 9† 31 ± 9†
L-IPC + PCP 6 ± 1 6 ± 1 33 ± 7‡ 27 ± 5‡ 24 ± 5‡
H-IPC + PCP 6 ± 2 6 ± 1 20 ± 8‡, 16 ± 9‡, 11 ± 6‡,
Che + PCP 7 ± 2 7 ± 2 58 ± 12 52 ± 13§ 48 ± 12§
Che + L-IPC + PCP 7 ± 2 7 ± 2 55 ± 12§,** 46 ± 12** 41 ± 11**
Che + H-IPC + PCP 7 ± 2 7 ± 2 50 ± 14*,*,* 36 ± 15*,* 33 ± 15*,**
Data are expressed as mean ± SD. 
L-IPC, Low-grade IPC; H-IPC, high-grade IPC; Che, chelerythrine.
*P < .05, †P < .01, and ‡P < .001 compared with control hearts.
§P < .05, P < .01, and ¶P < .001 compared with respective IPC without chelerythrine.
#P < .05, **P < .01, and ††P < .001 compared with PCP among the PCP-treated groups.
hearts with low-grade IPC than in control hearts, and the
recovery was further enhanced by high-grade IPC.
Chelerythrine had no significant effect on LVDP in the
normally perfused hearts but significantly reversed the
depression of LVDP after high-grade IPC. Although pre-
treatment with chelerythrine alone had no significant
effect on the recovery of LVDP during reperfusion com-
pared with that of control hearts, chelerythrine abolished
the improvement of LVDP recovery conferred by low- or
high-grade IPC during reperfusion.
HR was not affected during either grade of IPC. The
recovery of HR during reperfusion was significantly
greater in the hearts with low- or high-grade IPC com-
pared with that in control hearts. The improvement of
HR recovery conferred by IPC was abolished by pre-
treatment with chelerythrine.
CF was significantly increased by both grades of IPC,
and the increase in CF was more prominent with high-
grade than low-grade IPC. CF recovery during reperfu-
sion was significantly greater in the hearts with low- or
high-grade IPC compared with that in control hearts.
Chelerythrine had no significant effect on CF in the
normally perfused hearts or the hearts undergoing IPC.
However, pretreatment with chelerythrine significantly
inhibited the improvement of CF recovery conferred by
both grades of IPC during reperfusion.
LVEDP remained unchanged after either grade of
IPC. During reperfusion, both grades of IPC decreased
LVEDP significantly compared with values in control
hearts, although high-grade IPC was more effective in
lowering LVEDP. Pretreatment with chelerythrine had
no significant effect on LVEDP during reperfusion in
the hearts without IPC. Chelerythrine, however, abol-
ished the LVEDP-lowering effect of IPC.
Effect of IPC and PCP on cardiac performance.
Table II shows the effect of PCP combined with or with-
out IPC on cardiac performance in the isolated rat heart.
Hemodynamic data of the control hearts shown in Table
I were used for the comparison between unprotected
ischemia and PCP. Preischemic variables of cardiac per-
formance by treatment with low- or high-grade IPC with
or without chelerythrine was comparable with those
observed in the hearts that did not undergo PCP. The
recovery of LVDP during reperfusion was significantly
greater in the hearts with PCP compared with that in con-
trol hearts, but there was no further improvement in
LVDP when combined with low-grade IPC. In contrast,
the enhanced recovery of LVDP conferred by PCP during
reperfusion was significantly potentiated by high-grade
IPC. The improvement of LVDP recovery conferred by
PCP in combination with or without IPC was significant-
ly inhibited by pretreatment with chelerythrine.
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Fig 2.  Creatine kinase release. Creatine kinase activities were measured in coronary effluent collected during 30
minutes of reperfusion. L-IPC, Low-grade IPC; H-IPC, high-grade IPC; Che, 5 µmol/L chelerythrine. Each bar
graph represents mean ± SD of 7 experiments (control and PCP) or 6 experiments. *P < .05, **P < .01, and ***P
< .001 compared with control. #P < .05 and ##P < .01 compared with respective IPC without chelerythrine. †P <
.05 compared with PCP.
The recovery of HR during reperfusion was signifi-
cantly greater in the hearts with PCP compared with
that in control hearts. Low-grade IPC failed to enhance
the recovery of HR conferred by PCP. However, high-
grade IPC was capable of potentiating the recovery of
HR conferred by PCP. Pretreatment with chelerythrine
abolished the recovery of HR during reperfusion in the
hearts with PCP in combination with or without IPC.
CF recovery during reperfusion was significantly
greater in the hearts with PCP compared with that in
control hearts. No further increase in CF during reper-
fusion was noted when combined with low-grade IPC.
In contrast, PCP preceded by high-grade IPC signifi-
cantly increased CF during reperfusion compared with
PCP alone or in combination with low-grade IPC.
Pretreatment with chelerythrine significantly inhibited
the improvement of CF recovery conferred by PCP in
combination with or without IPC.
LVEDP was significantly lower in the hearts treated
with PCP during reperfusion compared with that in
control hearts. Low-grade IPC, however, failed to
enhance the LVEDP-lowering effect of PCP during
reperfusion. In contrast, high-grade IPC potentiated the
LVEDP-lowering effect of PCP during reperfusion.
Pretreatment with chelerythrine significantly reversed
the LVEDP-lowering effect of PCP combined with or
without IPC.
Effect of IPC and PCP on time to onset of con-
tracture, time to peak of contracture, and peak con-
tracture. We analyzed the time course and magnitude
of ischemic contracture in an attempt to solve an issue
of qualitative difference between IPC and PCP because
IPC and PCP produce a differential effect on the occur-
rence of ischemic contracture despite a comparable
cardioprotective effect.26 Time to onset of ischemic
contracture (TTC) was defined as the time after
ischemia to reach an increase of 5 mm Hg in LVEDP
from the preischemic value. TTC was significantly
shortened by low-grade and high-grade IPC compared
with TTC of control hearts (Table III). Pretreatment
with chelerythrine significantly potentiated IPC-
induced shortening of TTC. In contrast, PCP signifi-
cantly prolonged TTC compared with TTC in control
hearts. Low-grade and high-grade IPC significantly
shortened PCP-induced prolongation of TTC.
Pretreatment with chelerythrine significantly shortened
TTC after PCP in combination with or without IPC.
Similarly, time to peak of contracture (TPC) was sig-
nificantly shortened by low-grade and high-grade IPC
and was significantly prolonged by PCP compared
with TPC in control hearts. Pretreatment with chelery-
thrine significantly potentiated IPC-induced shortening
of TPC and reversed PCP-induced prolongation of
TPC.
Peak contracture was significantly enhanced by IPC
compared with that of control hearts and was potentiat-
ed by pretreatment with chelerythrine. PCP significant-
ly mitigated peak contracture compared with that found
in control hearts. However, PCP-induced amelioration
of peak contracture was reversed by pretreatment with
chelerythrine.
Ischemic contracture was gradually attenuated after
reaching peak contracture in all the hearts. However,
the magnitude of contracture at the end of ischemia
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Table III.  Time to contracture, time to peak of contracture, peak contracture, and end-ischemic contracture
TTC TPC Peak contracture End-ischemic contracture
(min) (min) (mm Hg) (mm Hg)
Control (n = 7) 12.6 ± 1.8 20.3 ± 2.4 49 ± 5 44 ± 7
L-IPC (n = 6) 8.3 ± 0.9‡ 14.9 ± 1.7‡ 56 ± 5* 50 ± 9
H-IPC (n = 6) 6.2 ± 1.0‡ 12.2 ± 1.4‡ 59 ± 5† 52 ± 7
Che (n = 6) 12.3 ± 2.0 20.8 ± 2.2 54 ± 6 50 ± 8
Che + L-IPC (n = 6) 6.6 ± 1.2‡,§ 11.5 ± 1.2‡, 64 ± 7†,§ 55 ± 7*
Che + H-IPC (n = 6) 4.7 ± 0.6‡,§ 9.7 ± 0.8‡, 70 ± 7‡,§ 60 ± 8†
PCP (n = 7) 20.5 ± 2.1‡ 27.4 ± 3.0‡ 38 ± 7† 34 ± 6*
L-IPC + PCP (n = 6) 15.0 ± 1.6*,†† 21.8 ± 1.7** 47 ± 6# 43 ± 4#
H-IPC + PCP (n = 6) 14.5 ± 1.8†† 20.7 ± 1.9†† 50 ± 5** 45 ± 7#
Che + PCP (n = 6) 15.8 ± 2.0*,** 21.9 ± 1.9** 49 ± 5# 44 ± 7#
Che + L-IPC + PCP (n = 6) 11.8 ± 1.2,†† 18.8 ± 1.3,†† 54 ± 5§,** 46 ± 5#
Che + H-IPC + PCP (n = 6) 11.5 ± 1.9§,†† 18.0 ± 2.2,†† 58 ± 7*,§,†† 50 ± 4**
Data are expressed as mean ± SD. L-IPC, Low-grade IPC; H-IPC, high-grade IPC; Che, chelerythrine.
*P < .05, †P < .01, and ‡P < .001 compared with control hearts.
§P < .5, P < .1, and ¶P < .001 compared with respective IPC without chelerythrine.
#P < .05, **P < .01, and ††P < .001 compared with PCP among the PCP-treated groups.
remained significantly greater in the hearts pretreated
with chelerythrine and IPC compared with that found
in the control hearts. It also remained significantly
greater in the hearts undergoing PCP pretreated with
IPC in the presence or absence of chelerythrine com-
pared with PCP alone.
Effect of IPC on creatine kinase release. Creatine
kinase release during reperfusion was significantly
inhibited by low-grade or high-grade IPC compared
with that of control hearts (Fig 2). Chelerythrine alone
had no significant effect on creatine kinase release dur-
ing reperfusion. However, inhibition of creatine kinase
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Fig 3.  PKC isoform distribution. Relative distribution of PKC α, δ, and ε in the membrane fraction over the cytosol
fraction was calculated as described in the “Materials and methods” section. Open bars, Experimental groups with-
out PCP; filled bars, experimental groups with PCP. L-IPC, Low-grade IPC; H-IPC, high-grade IPC; Che, 5
µmol/L chelerythrine. Each bar graph expresses mean ± SD of 5 experiments. *P < .05, **P < .01, and ***P <
.001 compared with control hearts. #P < .05 and ##P < .01 compared with respective IPC without chelerythrine.
†P < .05, ††P < .01, and †††P < .001 compared with PCP.
release conferred by IPC was reversed by pretreatment
with chelerythrine. Creatine kinase release was also
significantly inhibited by PCP. However, combination
with low-grade IPC failed to enhance the inhibition of
creatine kinase release conferred by PCP. In contrast,
high-grade IPC was capable of potentiating creatine
kinase release inhibition conferred by PCP.
Pretreatment with chelerythrine reversed creatine
kinase release inhibition conferred by PCP and both
grades of IPC.
Effect of IPC and PCP on membrane transloca-
tion of PKC isoforms. The effect of IPC on transloca-
tion of PKC isoforms to the membrane just before 35
minutes of ischemia is illustrated in Fig 3. Both low-
and high-grade IPC significantly increased distribution
of Ca2+-dependent PKC isoform α in the membrane
fraction. However, only high-grade IPC was capable of
redistributing Ca2+-independent PKC isoforms δ and ε
to the membrane. Chelerythrine inhibited translocation
of PKC α to the membrane in the hearts with low-grade
IPC. Chelerythrine also inhibited translocation of all of
3 PKC isoforms to the membrane in the hearts with
high-grade IPC.
Membrane translocation of PKC was also assessed in
the hearts with PCP. It was found that PCP alone
increased distribution of PKC α to the membrane.
There was no further increase in distribution of PKC α
to the membrane by preceding low-grade IPC. High-
grade IPC followed by PCP, however, significantly
increased distribution of PKC δ and ε to the membrane
in addition to PKC α. Chelerythrine inhibited translo-
cation of PKC α to the membrane in the hearts under-
going PCP with or without preceding low-grade IPC
and all 3 PKC isoforms in the hearts with preceding
high-grade IPC.
Discussion
The efficacy of IPC on myocardial protection under
PCP has been a matter of debate.4-9 The inability of
IPC to confer additive myocardial protection when
combined with PCP may have been due to inappropri-
ate IPC challenges. Use of a too-short period of
ischemia as an IPC protocol cannot produce IPC sig-
naling strong enough to induce myocardial protection.
On the other hand, repeating an extended period of
ischemia as an IPC protocol deteriorates the recovery
of myocardial function by simply imposing excessive
ischemic stress before a sustained period of ischemia.
Therefore, it is extremely important that any IPC pro-
tocols should be proven to be effective in the experi-
mental models with unprotected ischemia before appli-
cation to PCP. However, IPC protocols that are capable
of inducing significant myocardial protection against
unprotected ischemia have been found to confer no
additional myocardial protection when combined with
PCP.7,8 Therefore the present study was undertaken to
investigate the mechanism underlying differences in
the efficacy of IPC on myocardial protection when
combined with PCP. The major finding of the present
study was that low-grade IPC induced by 5 cycles of 1
minute of ischemia and 5 minutes of reperfusion failed
to enhance functional improvement and creatine kinase
release inhibition conferred by PCP, whereas high-
grade IPC induced by 3 cycles of 5 minutes of ischemia
and 5 minutes of reperfusion potentiated functional
recovery and creatine kinase release inhibition over
PCP alone. This observation indicates that only high-
grade IPC can enhance myocardial protection con-
ferred by PCP. Five cycles of 1 minute of ischemia and
5 minutes of reperfusion was chosen as a low-grade
IPC because this protocol matches a time frame of
high-grade IPC induced by 3 cycles of 5 minutes of
ischemia, which is known to induce optimum cardio-
protection in a number of animal models. A variety of
experimental protocols could induce low-grade or
high-grade IPC, although the duration and number of
cycles of ischemia and reperfusion to induce low-grade
or high-grade IPC may differ between species and
experimental models.
The failure of low-grade IPC to enhance myocardial
protection induced by PCP and the ability of high-
grade IPC to potentiate it have suggested that low-
grade IPC and PCP share a common mechanism of
myocardial protection, whereas high-grade IPC pro-
vokes additional mechanisms. It is now evident that
PKC plays a pivotal role in IPC-mediated myocardial
protection.26,27 The participation of PKC-mediated
intracellular events in IPC-induced myocardial protec-
tion has been suggested by studies with structurally
distinct PKC inhibitors, such as chelerythrine,
calphostin C, and bisindolylmaleimide, which have
consistently inhibited IPC-induced myocardial protec-
tion with some exceptions.18 Although those PKC
inhibitors are relatively specific for PKC compared
with the nonspecific protein kinase inhibitor stau-
rosporine, none of them possess apparent PKC isoform
selectivity.28 Thus, the chelerythrine used in the present
study was expected to inhibit all the PKC isoforms test-
ed. Moreover, the variety of intracellular events pro-
voked by PKC are known to be isoform dependent in
that individual PKC isoforms could play a distinct role
in myocardial protection. For example, Ca2+-dependent
PKC isoform α is activated by IPC, phorbol esters, and
Ca2+.29 The present study has also provided the evi-
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dence that PCP alone induces translocation of PKC α
to the membrane, and chelerythrine completely abro-
gated myocardial protection afforded by PCP. The
mechanism for PCP-induced activation of PKC α is not
clear at present but is probably mediated by a transient
increase in intracellular Ca2+. It has been demonstrated
that bolus infusion of a high concentration of CaCl2
into the coronary arteries or a brief period of Ca2+
depletion and Ca2+ repletion (induction of Ca2+ para-
dox) confers myocardial protection against ischemic
injury.29,30 A high extracellular potassium content is
also known to increase intracellular Ca2+ through volt-
age-dependent Ca2+ channels.31,32 Our previous study
demonstrated that PCP provoked a transient increase in
intracellular Ca2+ that significantly inhibited an
increase in intracellular Ca2+ during subsequent cardio-
plegic preservation and reperfusion in the intact guinea
pig heart.33 Thus, a transient increase in intracellular
Ca2+ and subsequent activation of PKC α before a sus-
tained period of ischemia may be a common denomi-
nator of myocardial protection induced by low-grade
IPC and PCP. However, PKC α activation is transient,
and its efficacy on myocardial protection may be limit-
ed, whereas activation of the Ca2+-independent PKC
isoforms δ and ε is long lasting.17 A number of recent
studies have substantiated the critical importance of
PKC δ and ε in mediating cardiomyocyte protection
against hypoxia- or ischemia-induced cell
death.14,25,35,36 Our study demonstrating that only high-
grade IPC activated PKC δ and ε and conferred superi-
or myocardial protection over low-grade IPC also
points to the same conclusion.
Although the present study has suggested that
myocardial protection conferred by low-grade IPC and
PCP is mediated at least in part by the same mechanism
(ie, Ca2+-dependent PKC activation), the functional
consequence during ischemia was markedly different
between IPC and PCP. PCP delays, and IPC acceler-
ates, ischemic contracture. Such enhanced ischemic
contracture after IPC has already been documented by
Otani and coworkers8 and Kolocassides and cowork-
ers.7 Because these studies demonstrated no apparent
correlation between the magnitude of ischemic con-
tracture and ultimate myocardial protection, the signif-
icance of delaying ischemic contracture in myocardial
protection under PCP remains unknown. However, the
delayed occurrence of ischemic contracture by PCP is
likely to be related to preservation of adenosine triphos-
phate (ATP) caused by rapid cessation of electrical and
mechanical activities in light of the fact that ischemic
contracture is induced primarily by depletion of ATP.37
However, our study has raised the possibility that PKC
α activation is involved in the alleviation of ischemic
contracture because pretreatment with chelerythrine
accelerated ischemic contracture induced by low-grade
and high-grade IPC and reversed the contracture-ame-
liorating effect of PCP, although it is unclear whether
PKC α activation promotes ATP preservation. ATP
preservation may be crucial in myocardial protection
particularly in the hearts with high-grade IPC, given
that high-grade IPC depletes ATP more drastically than
low-grade IPC before a sustained period of ischemia
that could discount the efficacy of high-grade IPC.
Thus, high-grade IPC followed by oxygenated PCP
resumes myocardial ATP before a sustained period of
ischemia. This assumption may explain why high-
grade IPC in combination with PCP conferred superior
myocardial protection over high-grade IPC alone
despite an equivalent magnitude of activation of all the
PKC isoforms.
Another important finding of our study is that high-
grade IPC gave rise to a significant decrease of LVDP
during the IPC challenge, and chelerythrine reversed the
depression of LV contractility. This observation indicates
that high-grade IPC-inducible activation of PKC is
involved in myocardial stunning. Because the mechanism
of myocardial stunning associated with a brief period of
ischemia remains elusive, participation of PKC in
myocardial stunning warrants further investigation.
Limitations of the study. Although the present study
has demonstrated IPC grade–dependent enhancement
of myocardial protection under PCP, there are concerns
as to whether the same phenomenon takes place in a
wide variety of species and experimental models.
Isoforms of PKC activated in response to ischemia are
known to be different among the species. Unlike in
rats, IPC induces selective translocation of PKC ε and
η in rabbits.25 The PKC isoforms that are activated by
IPC and are responsible for myocardial protection
remain unknown in human subjects. Developmental
differences in regulation of PKC isoforms should also
be considered.14 In addition, the temperature that we
have studied is normothermia throughout the experi-
ment. In the majority of cardiac operations, human
hearts undergo some sort of hypothermic protection.
Such a difference in myocardial temperature during
PCP and ischemia may influence the response to IPC
because PKC activation is temperature dependent.
Modality of PCP may also affect the efficacy of com-
bined IPC treatment on myocardial protection. Our
study used 5 minutes of infusion of normothermic oxy-
genated crystalloid PCP. This modality of PCP mimics,
but is not identical to, that introduced in warm blood
cardioplegia. Oxygenated and substrate-rich PCP solu-
tions could resume a myocardial energy level depleted
by prior IPC challenges, as mentioned before, which
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confer more salutary effects on myocardial protection
than introducing IPC in combination with nonoxy-
genated PCP solutions. Finally, validity of interpreta-
tions of the present data critically relies on the speci-
ficity of the PKC inhibitor chelerythrine. Although the
concentration of chelerythrine used in our study is
known to be specific for PKC inhibition, involvement
of unknown effects of chelerythrine in modulation of
IPC- and PCP-induced myocardial protection cannot
be ruled out. Further studies with isoform-specific PKC
inhibitors or PKC gene-modified animals will be nec-
essary to address this issue. 
Clinical implications. Numerous investigators have
attempted to take advantage of IPC for myocardial pro-
tection during coronary angioplasty and coronary
artery bypass operation.38 However, the efficacy of IPC
in the clinical setting of coronary interventions has not
been clearly delineated. Although our present study
indicates that low-grade IPC may be useful, at least
during coronary interventions, such as coronary angio-
plasty and off-pump coronary artery bypass operation
that do not make use of PCP, using high-grade IPC to
enhance myocardial protection under PCP may not be
encouraged in clinical practice. This is because the
graded phenomenon of IPC has not been demonstrated
in human subjects, and clinical trials to identify optimal
IPC protocols may be limited from an ethical point of
view. For this reason, greater effort should be exerted to
invent pharmacologic tools that are capable of inducing
activation of Ca2+-independent PKC isoforms to
enhance myocardial protection under PCP. Pharma-
cologic preconditioning with adenosine has been
shown to be efficacious in myocardial protection under
PCP.10 This enhanced myocardial protection by adeno-
sine may be attributed to activation of PKC δ.39 It has
also been reported that 1,4-benzothiazepine derivative
JTV519 confers a strong protective effect against Ca2+
overload–induced myocardial injury through specific
activation of the PKC δ isoform in the rat ventricular
myocardium.40 In addition, PKC ε activators, such as
phorbol esters, epinephrine, and endothelin,16 may be
used for pharmacologic preconditioning under PCP.
Better understanding of the molecular biology of PKC
signaling would allow  development of improved pre-
conditioning strategies for cardiac operations.
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